Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1.

"Disclosures Dr Fudim was supported by the National Heart, Lung, and Blood Institute (NHLBI; K23HL151744), the American Heart Association (20IPA35310955), Doris Duke, Bayer, Bodyport, and Verily. He receives consulting fees from Abbott, Alio Health, Alleviant, Audicor, AxonTherapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Cadence, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, EKO, Feldschuh Foundation, Fire1, Gradient, Intershunt, Medtronic, NIMedical, NXT Biomedical, Pharmacosmos, PreHealth, ReCor, Shifamed, Splendo, Sumacor, SyMap, Verily, Vironix, Viscardia, and Zoll. Dr Sauer reports consulting for Abbott, Medtronic, Edwards Lifesciences, Boston Scientific, Impulse Dynamics, Story Health, and General Prognostics. Dr Sauer also reports significant research funding from Abbott, General Prognostics, and Impulse Dynamics, as well as serving on the clinical trial steering committees for Boston Scientific, Biotronik, Abbott, Impulse Dynamics, Story Health, and General Prognostics. Drs Yazdi and Ozonat are employees at Bodyport Inc. S. Smith and C. Centen are founders and employees of Bodyport Inc. Dr DeVore reports research funding through his institution from the American Heart Association, Biofourmis, Bodyport, Cytokinetics, American Regent Inc, the NHLBI, Novartis, and Story Health. He also provides consulting services for and receives honoraria from Abiomed, AstraZeneca, Cardionomic, InnaMed, LivaNova, Natera, Novartis, Procyrion, Story Health, Vifor, and Zoll. He has also received nonfinancial support from Abbott for educational and research activities. The other authors report no conflicts."

"Sources of Funding The SCALE-HF (Surveillance and Alert-Based Multiparameter Monitoring to Reduce Worsening Heart Failure Events) program is sponsored by Bodyport Inc."

"Registration:: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04882449."